Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children
| Autor: | Joe McDonough, G. Lesa, Franca Ligas, Miguel Rivera, Ira Jacobs, Andrew D.J. Pearson, Malcolm A. Smith, Maureen Hattersley, Dominik Karres, Aundrietta D. Duncan, Nada Jabado, Daniel D. De Carvalho, Koen Norga, Peter C. Adamson, Donna Ludwinski, Gregory H. Reaman, Brian Gadbaw, Elizabeth Fox, Samuel C. Blackman, Mark W. Kieran, Gilles Vassal, Christian Baumann, Vickie Buenger, Delphine Heenen, Scott A. Armstrong, Michael J. Kelly, Amy Barone, Adrian Senderowicz, Franck Bourdeaut, Martha Donoghue, Tilmann Taube, Peter T.C. Ho, Lynley V. Marshall, Patrick A. Brown, Michael L. Meyers, Kimberly Stegmaier, Zariana Nikolova, Susan L. Weiner |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty Epigenetic modifier business.industry Epigenome DOT1L Food and drug administration 03 medical and health sciences Therapeutic approach 030104 developmental biology 0302 clinical medicine Oncology Drug development 030220 oncology & carcinogenesis New product development medicine Epigenetics Intensive care medicine business |
| Zdroj: | European Journal of Cancer. 139:135-148 |
| ISSN: | 0959-8049 |
| Popis: | The fifth multistakeholder Paediatric Strategy Forum focussed on epigenetic modifier therapies for children and adolescents with cancer. As most mutations in paediatric malignancies influence chromatin-associated proteins or transcription and paediatric cancers are driven by developmental gene expression programs, targeting epigenetic mechanisms is predicted to be a very important therapeutic approach in paediatric cancer. The Research to Accelerate Cures and Equity (RACE) for Children Act FDARA amendments to section 505B of the FDC the biology is multifaceted and new targets are frequently emerging. Targeting epigenetic mechanisms in paediatric malignancy has in most circumstances yet to reach or extend beyond clinical proof of concept, as many targets do not yet have available investigational drugs developed. Eight classes of medicinal products were discussed and prioritised based on the existing level of science to support early evaluation in children: inhibitors of menin, DOT1L, EZH2, EED, BET, PRMT5 and LSD1 and a retinoic acid receptor alpha agonist. Menin inhibitors should be moved rapidly into paediatric development, in view of their biological rationale, strong preclinical activity and ability to fulfil an unmet clinical need. A combination approach is critical for successful utilisation of any epigenetic modifiers (e.g. EZH2 and EED) and exploration of the optimum combination(s) should be supported by preclinical research and, where possible, molecular biomarker validation in advance of clinical translation. A follow-up multistakeholder meeting focussing on BET inhibitors will be held to define how to prioritise the multiple compounds in clinical development that could be evaluated in children with cancer. As epigenetic modifiers are relatively early in development in paediatrics, there is a clear opportunity to shape the landscape of therapies targeting the epigenome in order that efficient and optimum plans for their evaluation in children and adolescents are developed in a timely manner. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect